| __timestamp | Takeda Pharmaceutical Company Limited | Vertex Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 612613000000 | 305409000 |
| Thursday, January 1, 2015 | 650773000000 | 377080000 |
| Friday, January 1, 2016 | 619061000000 | 432829000 |
| Sunday, January 1, 2017 | 628106000000 | 496079000 |
| Monday, January 1, 2018 | 717599000000 | 557616000 |
| Tuesday, January 1, 2019 | 964737000000 | 658498000 |
| Wednesday, January 1, 2020 | 875663000000 | 770456000 |
| Friday, January 1, 2021 | 886361000000 | 840100000 |
| Saturday, January 1, 2022 | 997309000000 | 944700000 |
| Sunday, January 1, 2023 | 1053819000000 | 1136600000 |
| Monday, January 1, 2024 | 1053819000000 | 1464300000 |
Data in motion
In the ever-evolving pharmaceutical industry, understanding the financial strategies of leading companies is crucial. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Vertex Pharmaceuticals Incorporated and Takeda Pharmaceutical Company Limited from 2014 to 2023.
Takeda's SG&A expenses have shown a steady increase, rising by approximately 72% over the decade, peaking at over 1 trillion yen in 2023. This growth reflects Takeda's expansive global operations and strategic investments. In contrast, Vertex Pharmaceuticals, a leader in innovative therapies, has seen its SG&A expenses grow by nearly 272% during the same period, reaching over 1 billion dollars in 2023. This surge underscores Vertex's aggressive market expansion and R&D investments.
While Takeda's expenses dwarf those of Vertex, the latter's rapid growth rate highlights its dynamic approach in the competitive pharmaceutical landscape.
Selling, General, and Administrative Costs: AstraZeneca PLC vs Vertex Pharmaceuticals Incorporated
Who Optimizes SG&A Costs Better? Sanofi or Takeda Pharmaceutical Company Limited
Bristol-Myers Squibb Company or Vertex Pharmaceuticals Incorporated: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and Takeda Pharmaceutical Company Limited
Who Optimizes SG&A Costs Better? Vertex Pharmaceuticals Incorporated or Exelixis, Inc.
Vertex Pharmaceuticals Incorporated or Arrowhead Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Vertex Pharmaceuticals Incorporated vs Viridian Therapeutics, Inc.
Comparing SG&A Expenses: Takeda Pharmaceutical Company Limited vs Sarepta Therapeutics, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Takeda Pharmaceutical Company Limited and Corcept Therapeutics Incorporated
Selling, General, and Administrative Costs: Takeda Pharmaceutical Company Limited vs Protagonist Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Takeda Pharmaceutical Company Limited and Iovance Biotherapeutics, Inc.
Comparing SG&A Expenses: Takeda Pharmaceutical Company Limited vs Ligand Pharmaceuticals Incorporated Trends and Insights